There are important decisions being made about gene patenting that will impact how we move forward with genetic research and clinical medicine.
Excerpt from the article by Andrew Pollack
“The issue of gene patents has long been a controversial and emotional one. Opponents say that genes are products of nature, not inventions, and should be the common heritage of mankind. They say that locking up basic genetic information in patents actually impedes medical progress. Proponents say genes isolated from the body are chemicals that are different from those found in the body and therefore are eligible for patents.
The Patent and Trademark Office has sided with the proponents and has issued thousands of patents on genes of various organisms, including on an estimated 20 percent of human genes.
But in its brief, the government said it now believed that the mere isolation of a gene, without further alteration or manipulation, does not change its nature.”
The article references the following brief, which can be accessed at: http://graphics8.nytimes.com/packages/pdf/business/genepatents-USamicusbrief.pdf